Saturday 17 October 2026
Export CLSDQ’s income statement to Excel — free account
Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
0.25
0.00
0.00%
Follow CLSDQ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 4 | 4 | 5 | 2 | 4 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
4.41 | (2.71) | (10.92) | (11.18) | (13.44) | 12.95 | (7.78) | (13.68) | (22.08) |
P/S ratio |
236.37 | 527.78 | 95.37 | 50.97 | 16.15 | 5.44 | 55.17 | 9.70 | 42.16 |
Altman Z″-Score (non-manufacturers) |
7.32 | (14.35) | (21.88) | (32.28) | (45.76) | (5.69) | (16.44) | (31.50) | (50.16) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | — | — | (1.63) |
P/Operating CF |
(19.04) | (12.06) | (1.36) | 65.57 | (28.74) | 31.84 | (13.06) | 161.15 | (13.35) |
P/B ratio |
1.72 | 8.50 | 1.39 | 9.93 | 14.55 | 4.24 | 6.90 | 0.00 | 0.00 |
Price to Tangible BV |
1.72 | 8.50 | 1.39 | 9.93 | 14.55 | 4.24 | 6.90 | 0.00 | 0.00 |
EV/Sales |
94.74 | 441.89 | 5.80 | 42.94 | 14.13 | 4.46 | 19.84 | 6.35 | 30.95 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.17) | (2.98) | (0.03) | (3.45) | (8.50) | (12.29) | (1.97) | (2.88) | (2.09) |
EV/FCF |
(2.17) | (2.97) | (0.03) | (3.44) | (8.47) | (12.22) | (1.93) | (2.62) | (2.01) |
Quick Ratio |
15.46 | 2.78 | 3.90 | 2.07 | 1.74 | 8.71 | 8.34 | 4.31 | 4.28 |
Current Ratio |
15.59 | 2.90 | 4.10 | 2.31 | 1.82 | 9.08 | 8.54 | 4.42 | 4.44 |
Net Debt/EBITDA |
3.03 | 0.51 | 0.37 | 0.58 | 0.92 | 67.79 | 1.60 | 1.17 | 0.69 |
Debt/Assets |
8.94% | 19.78% | 22.61% | 19.24% | 5.13% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.11 | 0.37 | 0.42 | 0.46 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.06 | 0.34 | 0.95 | 0.03 | 0.19 | 0.06 |
Operating CF/Net income |
0.88 | 0.87 | 0.96 | 0.88 | 0.72 | (28.55) | 0.41 | 0.56 | 0.72 |
Capex/Depreciation |
(0.02) | (0.84) | 0.20 | (0.15) | (0.18) | 0.00 | (1.70) | (26.52) | 8.65 |
Interest Coverage |
— | — | — | — | — | — | (9.07) | (2.65) | (2.95) |
| (147.90%) | (126.73%) | (367.79%) | (176.96%) | (182.83%) | 1.61% | (135.63%) | 1,224.69% | 125.45% | |
| (48.89%) | (94.13%) | (195.76%) | (86.80%) | (79.01%) | 1.21% | (69.95%) | (76.15%) | (116.16%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (5.20%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(32.76%) | (221.99%) | (249.02%) | (207.11%) | (211.97%) | 1.00% | (74.25%) | (123.49%) | (174.33%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.42 | 0.00 | 20.72 | 111.21 |
Research and Development Expense of Revenue |
3,741.35% | 14,218.26% | 227,636.67% | 720.57% | 190.94% | 62.68% | 1,479.28% | 253.42% | 1,117.19% |
Selling, General and Administrative Expense of Revenue |
1,204.42% | 2,811.59% | 48,946.67% | 774.00% | 136.26% | 39.44% | 886.96% | 144.29% | 709.56% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
252.69% | 975.07% | 15,950.00% | 212.24% | 45.60% | 17.09% | 368.05% | 51.08% | 271.21% |
Graham Net Nets |
0.58 | 0.11 | 0.68 | 0.09 | 0.06 | 0.23 | 0.12 | (0.25) | (0.61) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.27 | 35.38 |
Earnings Yield |
(36.25%) | (32.25%) | (252.21%) | (28.95%) | (14.23%) | (0.36%) | (45.23%) | (41.07%) | (49.45%) |
Free Cash Flow Yield |
(18.49%) | (28.22%) | (240.94%) | (24.46%) | (10.33%) | (6.70%) | (18.59%) | (24.96%) | (36.60%) |
Revenue per Share |
0.59 | 0.20 | 0.01 | 0.85 | 2.54 | 7.58 | 0.33 | 2.00 | 0.34 |
Operating CF per Share |
(25.97) | (30.26) | (38.63) | (10.63) | (4.23) | (2.75) | (3.33) | (4.40) | (5.02) |
Capex per Share |
0.00 | (0.18) | (0.04) | (0.01) | (0.02) | 0.00 | (0.06) | (0.43) | (0.20) |
Free Cash Flow per Share |
(25.97) | (30.44) | (38.68) | (10.64) | (4.25) | (2.75) | (3.39) | (4.83) | (5.22) |
Cash per Share |
95.63 | 22.29 | 19.94 | 8.87 | 5.57 | 7.80 | 12.02 | 7.02 | 4.07 |
Shareholders Equity per Share |
81.94 | 12.68 | 11.52 | 4.38 | 2.83 | 9.73 | 2.64 | (3.86) | (7.89) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
81.94 | 12.68 | 11.52 | 4.38 | 2.83 | 9.73 | 2.64 | (3.86) | (7.89) |
Free Cash Flow |
(22.71) | (51.39) | (79.29) | (27.09) | (13.17) | (10.73) | (13.61) | (19.91) | (25.67) |
Working Capital |
78.91 | 25.68 | 32.47 | 14.32 | 8.18 | 37.50 | 43.62 | 23.31 | 16.48 |
Capital Expenditures |
0.00 | (0.31) | (0.09) | (0.02) | (0.05) | — | (0.25) | (1.78) | (0.98) |
Net Current Asset Value |
71.16 | 20.12 | 22.44 | 9.60 | 7.56 | 37.21 | 8.71 | (19.81) | (42.71) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.89 | 2.93 | 0.01 | 0.01 | 0.00 | 0.19 | 0.22 | 0.59 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.38 | 0.41 | (0.57) | 0.30 | 0.74 | 0.75 | 0.19 | 0.02 | (0.03) |
Cash ROIC |
(13.94%) | (76.63%) | (106.47%) | (69.64%) | (48.72%) | (15.69%) | (23.12%) | (153.08%) | 136.32% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 3.42 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.20 | 0.22 | 0.08 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,929.58 | 1,878.68 | 2,267.11 | 3,556.91 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | — | — | 5.23 | 0.49 |
Average Payables |
2.03 | 3.99 | 6.13 | 4.07 | 1.64 | 1.47 | 1.00 | 1.63 | 1.83 |
Average Assets |
52.93 | 62.65 | 42.31 | 35.45 | 23.05 | 31.11 | 47.10 | 42.66 | 29.57 |
Average Common Equity |
17.50 | 46.54 | 22.52 | 17.39 | 9.96 | 23.37 | 24.29 | (2.65) | (27.38) |
Columns are period end dates